Proton beam therapy in paediatric cancer: Anticipating the opening of the Australian Bragg Centre for Proton Therapy and Research.
Australian Bragg Centre for Proton Therapy and Research
paediatric cancer
proton beam therapy
radiotherapy
survivorship
Journal
Journal of medical imaging and radiation oncology
ISSN: 1754-9485
Titre abrégé: J Med Imaging Radiat Oncol
Pays: Australia
ID NLM: 101469340
Informations de publication
Date de publication:
25 Dec 2023
25 Dec 2023
Historique:
received:
31
08
2023
accepted:
09
12
2023
medline:
26
12
2023
pubmed:
26
12
2023
entrez:
25
12
2023
Statut:
aheadofprint
Résumé
Proton Beam Therapy (PBT) has the potential to improve paediatric cancer care by reducing radiation exposure and thus long-term toxicities. Ethical concerns and debates surrounding the treatment, such as eligibility and accessibility, are ongoing in Australia. The Australian Bragg Centre for Proton Therapy and Research (ABCPTR) (named after Sir William Henry Bragg who described the Bragg peak in his laboratory at the University of Adelaide in 1903) aims to increase access to PBT in Australasia and offer a patient-centred care approach. Research is underway to assess PBT's safety and cost-effectiveness, using tools including Normal Tissue Complication Probability (NTCP) models. Collaborative efforts are focused on developing tailored survivorship clinics to enhance patient follow-up and quality of life. With the anticipated opening of the ABCPTR, Australia is preparing to take a significant step in radiation oncology, offering new research opportunities and creating a publicly funded treatment centre. The initiative aims to balance treatment efficacy with patient care, setting the stage for a future in which radiation therapy will reduce long-term side effects compared to the current standard of care. The implementation of PBT in Australia represents a complex and promising approach to paediatric oncology. This article provides an overview of the current landscape, highlighting the potential benefits and challenges of a treatment that could redefine the quality of survivorship and contribute to global research and best clinical practice.
Identifiants
pubmed: 38146017
doi: 10.1111/1754-9485.13614
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Journal of Medical Imaging and Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Radiologists.
Références
Australian Childhood Cancer Registry, Cancer Council Queensland. Australian Childhood Cancer Statistics Online (1983-2018). CCQ, Brisbane, 2021.
Bishr MK, Zaghloul MS, Elmaraghi C et al. The radiotherapy utilization rate in pediatric tumors: an analysis of 13,305 patients. Radiother Oncol 2021; 154: 220-226.
Bhatnagar A, Deutsch M. The role for intensity modulated radiation therapy (IMRT) in pediatric population. Technol Cancer Res Treat 2006; 5: 591-595.
Meadows AT, Friedman DL, Neglia JP et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 2009; 27: 2356-2362.
Xiang M, Chang DT, Pollom EL. Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy. Cancer 2020; 126: 3560-3568.
van de Water TA, Bijl HP, Schilstra C, Pijls-Johannesma M, Langendijk JA. The potential benefit of radiotherapy with protons in head and neck cancer with respect to normal tissue sparing: a systematic review of literature. Oncologist 2011; 16: 366-377.
Takizawa D, Mizumoto M, Yamamoto T et al. A comparative study of dose distribution of PBT, 3D-CRT and IMRT for pediatric brain tumors. Radiat Oncol 2017; 12: 40.
Paulino AC, Mahajan A, Ye R et al. Ototoxicity and cochlear sparing in children with medulloblastoma: proton vs. photon radiotherapy. Radiother Oncol 2018; 128: 128-132.
Verma V, Simone CB 2nd, Mishra MV. Quality of life and patient-reported outcomes following proton radiation therapy: a systematic review. J Natl Cancer Inst 2018; 110: 341-353.
Kutanzi KR, Lumen A, Koturbash I, Miousse IR. Pediatric exposures to ionizing radiation: carcinogenic considerations. Int J Environ Res Public Health 2016; 13: 1057.
Indelicato DJ, Merchant T, Laperriere N et al. Consensus report from the Stockholm pediatric proton therapy conference. Int J Radiat Oncol Biol Phys 2016; 96: 387-392.
Hwang EJ, Gorayski P, Le H et al. Particle therapy toxicity outcomes: a systematic review. J Med Imaging Radiat Oncol 2020; 64: 725-737.
Hwang EJ, Gorayski P, Le H et al. Particle therapy tumour outcomes: an updated systematic review. J Med Imaging Radiat Oncol 2020; 64: 711-724.
American Society for Radiation Oncology. ASTRO PBT model policy [Internet]. American Society for Radiation Oncology, Arlington; 2022. [Cited 2 Aug 2023.] Available from URL: https://www.astro.org/ASTRO/media/ASTRO/Daily%20Practice/PDFs/ASTROPBTModelPolicy.pdf.
National Health Service. Standard operating procedure: process for applying for proton beam therapy and subsequent treatment centre allocation for eligible patients [Internet]. National Health Service, Leeds; 2019. [Cited 2 Aug 2023.] Available from URL: https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2019/03/Standard-Operating-Procedure_Proton-Beam-Therapy-treatment-application-process-and-centre-allocation.pdf.
Shrestha S, Bates JE, Liu Q et al. Radiation therapy related cardiac disease risk in childhood cancer survivors: updated dosimetry analysis from the Childhood Cancer Survivor Study. Radiother Oncol 2021; 163: 199-208.
Ishida Y, Sakamoto N, Kamibeppu K et al. Late effects and quality of life of childhood cancer survivors: part 2. Impact of radiotherapy. Int J Hematol 2010; 92: 95-104.
Bass JK, Hua CH, Huang J et al. Hearing loss in patients who received cranial radiation therapy for childhood cancer. J Clin Oncol 2016; 34: 1248-1255.
Jakacki RI, Goldwein JW, Larsen RL, Barber G, Silber JH. Cardiac dysfunction following spinal irradiation during childhood. J Clin Oncol 1993; 11: 1033-1038.
Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014; 64: 83-103.
Brinkman TM, Recklitis CJ, Michel G, Grootenhuis MA, Klosky JL. Psychological symptoms, social outcomes, socioeconomic attainment, and health behaviors among survivors of childhood cancer: current state of the literature. J Clin Oncol 2018; 36: 2190-2197.
Australian Government, Department of Health and Aged Care. Medical Treatment Overseas Program [Internet]. Australian Government, Australia; 2023. [Cited 2 Aug 2023.] Available from URL: https://www.health.gov.au/our-work/medical-treatment-overseas-program.
Penfold SN, Dell'Oro M, Gorayski P et al. Proton-to-photon comparative treatment planning guidelines for the Australian context. J Med Imaging Radiat Oncol 2023; 67: 320-328.
Jessop S, Penfold S, Gorayski P et al. If we build it, will they come? Modeling of public hospital care requirements for the Australian Bragg Centre for Proton Therapy and Research. Asia Pac J Clin Oncol 2023; 19: 525-532.
Australian Government, Department of Health and Aged Care, Medical Services Advisory Committee. 1638 - Proton beam therapy for paediatric and rare cancers [Internet]. Australian Government, Australia; 2020. [Cited 2 Aug 2023.] Available from URL: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1638-public.
Eaton BR, MacDonald SM, Yock TI, Tarbell NJ. Secondary malignancy risk following proton radiation therapy. Front Oncol 2015; 5: 261.
Stacchiotti S, Gronchi A, Fossati P et al. Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. Ann Oncol 2017; 28: 1230-1242.
D'Arienzo M, Masciullo SG, de Sanctis V, Osti MF, Chiacchiararelli L, Enrici RM. Integral dose and radiation-induced secondary malignancies: comparison between stereotactic body radiation therapy and three-dimensional conformal radiotherapy. Int J Environ Res Public Health 2012; 9: 4223-4240.
Burnet NG, Mackay RI, Smith E et al. Proton beam therapy: perspectives on the National Health Service England clinical service and research programme. Br J Radiol 2020; 93: 20190873.
Bygrave A, Whittaker K, Paul C, Fradgley EA, Varlow M, Aranda S. Australian experiences of out-of-pocket costs and financial burden following a cancer diagnosis: a systematic review. Int J Environ Res Public Health 2021; 18: 2422.
Lundkvist J, Ekman M, Ericsson SR, Jönsson B, Glimelius B. Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma. Cancer 2005; 103: 793-801.
Wiig S, Storm M, Aase K et al. Investigating the use of patient involvement and patient experience in quality improvement in Norway: rhetoric or reality? BMC Health Serv Res 2013; 13: 206.
Langendijk JA, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol 2013; 107: 267-273.
Ramaekers BL, Grutters JP, Pijls-Johannesma M, Lambin P, Joore MA, Langendijk JA. Protons in head-and-neck cancer: bridging the gap of evidence. Int J Radiat Oncol Biol Phys 2013; 85: 1282-1288.
Oeffinger KC, Mertens AC, Sklar CA et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355: 1572-1582.
Hwang E, Gorayski P, Thwaites D et al. Minimum data elements for the Australian Particle Therapy Clinical Quality Registry. J Med Imaging Radiat Oncol 2023; 67: 668-675.
Trans Tasman Radiation Oncology Group. TROG 21.12 - ASPIRE [Internet]. Australia New Zealand Clinical Trials Registry; 2022. [Cited 2 Aug 2023.] Available from URL: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12622000026729p.